Pfizer Receives Positive CHMP Opinion for VYNDAQEL® (tafamidis) for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
PharmiWeb,
-If approved by the European Commission (EC), tafamidis will be the first pharmacologic therapy in the EU for patients with…